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Abstract
Background: Older people are currently the fastest growing segment of the worldwide population. The present
study aimed to estimate propofol dose in older patients based on size descriptors measured by bioelectrical
impedance analysis (BIA).
Methods: A cross sectional study in adult and older patients with body mass index equal to or lower than 35 kg/
m2 was carried out. BIA and Clinical Frail Scale scoring were performed during pre-operative evaluation. Propofol
infusion was started at 2000 mg/h until loss of consciousness (LOC) which was defined by “loss of eye-lash reflex”
and “loss of response to name calling”. Total dose of propofol at LOC was recorded. Propofol plasma concentration
was measured using gas chromatography/ion trap-mass spectrometry.
Results: Forty patients were enrolled in the study. Total propofol dose required to LOC was lower in Age ≥ 65
group and a higher plasma propofol concentration was measured in this group. 60% of old patients were classified
as “apparently vulnerable” or “frail” and narrow phase angle values were associated with increasing vulnerability
scores. In the Age ≥ 65 group, the correlation analysis showed that the relationship between propofol dose and
total body weight (TBW) scaled by the corresponding phase angle value is stronger than the correlation between
propofol dose and TBW or fat free mass (FFM).
Conclusions: This study demonstrates that weight-based reduction of propofol is suitable in older patients;
however FFM was not seen to be more effective than TBW to predict the propofol induction dose in these
patients. Guiding propofol induction dose according to baseline frailty score should also be considered to estimate
individualized dosage profiles. Determination of phase angle value appears to be an easy and reliable tool to assess
frailty in older patients.
Trial registration: ClinicalTrials.gov Identifier: NCT02713698. Registered on 23 February 2016.
Keywords: Propofol induction dose, Older patients, Phase angle, Frailty
Background
Older people are currently the fastest growing segment of
the worldwide population, and older patients are increas-
ingly submitted to a multiplicity of surgical procedures [1,
2]. Physiologic changes and cognitive dysfunction associated
with age, the presence of multiple comorbidities, the use of
multiple medications and frailty increase the risk of older
patients to adverse postoperative outcomes [1]. As a result,
older people present a larger variation in terms of morbidity
and physiological characteristics, which affect the predict-
ability of their response to medications [3]. Variation in
frailty likely contributes to this heterogeneity but its effects
on pharmacokinetics (PK) and pharmacodynamics (PD) are
not yet well understood [3]. Consequently, chronological
age is a weak contributing factor of pharmacological re-
sponse. Age-related physiologic changes per se are not al-
ways clinically significant and should not result in the same
dose regimen alterations for all chronological old pa-
tients [3]. Despite these considerations, current guide-
lines recommend lower doses of anesthetic agents for
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all chronologically older patients [4–6]. For induction
of general anesthesia with propofol, it is generally rec-
ommended to decrease propofol dose from 40 mg
every 10 s (2–2.5 mg/kg) to 20 mg every 10 s (1–1.5
mg/kg) until induction onset [7].
Additionally, bolus dose recommendations for adult
non-obese patients are generally made as a function
of total body weight (TBW) [8]. Physiologic changes
that occur with aging, such as a decrease in total
body water, a decrease in lean body weight (LBW)
and an increase in body fat, may possibly require the
adjustment of propofol doses based on different
weight scalars [5, 9]. Mitchell et al. [9] have advo-
cated that LBW may be an alternative choice for drug
dose calculation in older patients. Nevertheless, the
adequacy of TBW or other size descriptors as predic-
tors of the propofol dose at LOC has not been stud-
ied yet in older patients.
Bioelectrical impedance analysis (BIA) is a reference
method for the assessment of body composition by
measuring resistance and reactance [9, 10]. Resistance
is associated with the quantity of water present in tis-
sues, and reactance is the resistive effect created by
the cell membranes and tissue interfaces [11]. Phase
angle can be calculated from resistance and reactance
[arc-tangent (Reactance/Resistance)*180°/π] and it
characterizes the relative effects of fluid (resistance)
and cellular membranes (reactance) of the body [11,
12]. Consequently, phase angle has been interpreted
as a determining factor of body cell mass, cell mem-
brane integrity, intra and extracellular water distribu-
tion and it has also been proposed as a biological
sign of cell death [10, 13]. The phase angle varies
with sex, age and body mass index (BMI) but the
average value for a healthy individual is generally
comprised between 6 and 9 degrees [14].
Phase angle evaluation has been suggested as a prog-
nostic factor in a number of clinical disorders, namely,
human immunodeficiency virus infection, liver cirrhosis,
chronic obstructive pulmonary disease, hemodialysis,
sepsis and lung, breast, colorectal and pancreatic cancer
[10]. BIA derived phase angle has also been proposed as
an objective measure to recognize frail patients [15].
More recently, Mullie et al. [12] concluded that phase
angle is strongly associated with sarcopenia and frailty in
older patients, and that it is a promising noninvasive de-
vice to assess frailty.
Given the physiologic changes in body composition asso-
ciated with aging, we planned to determine the appropriate
size descriptor, measured by bioelectrical impedance, to
estimate propofol induction dose in older patients. We also
proposed to assess changes in phase angle values in frail
patients. We hypothesized that LBW would be a more
appropriate dosing scalar to calculate propofol induction
dose in older patients and that old frail patients would re-
quire lower doses of propofol during induction of general
anesthesia.
Methods
This study was performed at Centro Hospitalar e
Universitário do Porto, Porto, Portugal, after Hospital
Review Board and Ethical Committee approvals (IRB:
N/REF.ª 2015.221(183-DEFI/165-CES) and it provides
secondary analyses of data registered at clinicaltrials.
gov under the reference NCT02713698 on 23
February 2016.
The main purpose of the research published in clinical
trials consisted in the development of a population
pharmacokinetic-pharmacodynamic model for propofol
when used for induction and maintenance of general
anesthesia. Secondarily, sectorial evaluations of the re-
sults focusing on the induction and maintenance phases
of anesthesia have also been conducted. The first study,
planned to assess the ability of body size descriptors to
estimate propofol induction dose in obese patients, has
already been published [16].
The proposed study is a cross sectional analytical
study and it conformed to the requirements of STROBE
(Strengthening the reporting of Observational studies in
epidemiology) statement. The whole anesthetic proced-
ure was standard except for additional body composition
assessment with body composition monitor (BCM, Fre-
senius Medical Care, Germany) and arterial blood sam-
ple. Written informed consent was obtained from all
subjects participating in the trial.
Patients
Adult patients (18–64 years), with ASA (American So-
ciety of Anesthesiology) physical status I to III and
BMI equal to or lower than 35 kg/m2 scheduled for
elective nose, ear or general surgery and older pa-
tients (with 65 or more years), with ASA physical sta-
tus I to III and BMI equal to or lower than 35 kg/m2
scheduled for orthopedic or elective nose or ear sur-
gery were included in the study.
Exclusion criteria included the presence of predict-
ive criteria for difficult airway management, dementia,
severe hepatic or renal insufficiency, significant
hemodynamic instability prior to the surgery and a
known allergy to propofol at the time of enrolment.
Patients with a pacemaker and pregnant women were
also excluded.
Analysis of body composition by bioelectrical impedance
BIA was performed by Body Composition Monitor
(BCM, Fresenius Medical Care, Germany) during pre-
operative evaluation in accordance with the manufac-
turer’s recommendations [17].
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Phase angle values at 50 kHz were registered and stan-
dardized values (z-score) were calculated based on refer-
ence values generated in a healthy German population
[18] according to sex, age and BMI.
The values of resistance and reactance obtained at 50
kHz were used to estimate fat free mass (FFM) or fat
mass (FM) based on specific predictive equations [19].
The equation proposed by Kyle et al. [20] was used in
adult patients and the equation proposed by Roubenoff
et al. [21] was used in older patients for the assessment
of FFM.
FFM Kyle equationð Þ ¼ −4:104þ 0; 518Height
2
Resistance
þ 0:231 TBW þ 0:130
 Reactanceþ 4:229 Sex
FFM Roubenoff equationð Þ
¼ −5:741þ 0; 4551Height
2
Resistance
þ 0:1405 TBW
þ 0:0573 Reactance þ 6:2467 Sex
Frailty assessment tools
The 9-point Clinical Frailty Scale (CFS) [22] developed
by Geriatric Medicine Research (Dalhousie University,
Halifax, Canada) was applied to each patient during pre-
operative assessment. The CFS was assigned from 1
(very fit) to 9 (terminally ill).
Anesthetic procedure
All patients were brought to the operating room
without premedication. In the operating room, con-
tinuous pulse oximetry, electrocardiography, invasive
blood pressure and neuromuscular blockade were ap-
plied in all patients. The bispectral index (BIS) was
monitored using a BIS VISTA™ Bilateral Monitoring
System (Covidien, Colorado, US) with a bilateral sen-
sor on the forehead of the patient.
Each subject received a standardized dose of fen-
tanyl (2 μg/kg) or a target controlled infusion of remi-
fentanil (pharmacokinetic model of Minto [23]) was
set at 3 ng/mL before propofol infusion. Propofol in-
fusion (using Orchestra™ Mobile stand, Fresenius Vial,
Brézins, France) was started at 2000 mg/h (33.3 mg/
min) until LOC, defined by “loss of eye-lash reflex”
and “loss of response to name calling”. Total dose of
propofol at LOC was recorded in all patients. After
LOC, rocuronium was administered, propofol infusion
rate was guided by the BIS and volume-controlled
ventilation was started in all patients. Ventilation
parameters setting were: tidal volume 7 ml/kg,
respiratory rate 12–14 cycles per minute to attain nor-
mocapnia and PEEP 5cmH2O.
Quantification of propofol concentration
Arterial blood samples were collected after LOC and
they were centrifuged (2862×g for 5 min) at the end of
the surgery. Serum samples were then preserved at −
80 °C until analysis.
Propofol concentration was determined by gas chro-
matography/ion trap-mass spectrometry (GC/IT-MS)
using the method described by Campos et al. [24]. The
concentration range for the calibration curve was de-
fined according to the expected serum concentrations
(0.25, 0.5, 1, 2, 4, 5 and 10 μg/mL).
Sample size
Literature shows a moderate relationship (r2 = 0.49)
between propofol induction dose and TBW in adult
patients with normal BMI [8]. To the author’s know-
ledge there is no previous study evaluating the rela-
tionship between TBW and propofol induction dose
in older patients. As a result, sample size consider-
ations were based on association analyses using the
Pearson correlation test. To detect a correlation of at
least 0.7 between propofol induction dose and TBW a
sample of at least 13 subjects was calculated to pro-
vide 80% power and a 0.05 level of significance.
Statistical methodology
The Shapiro-Wilk test was used to test for the
normality of data. Categorical variables are presented
as frequency (%). Continuous data are presented as
mean or median (coefficient of variation, CV %). For
comparison between groups, the Student’s t-test and
the Mann-Whitney-Wilcoxon test were used for con-
tinuous variables. The Fisher’s exact test was used for
categorical variables.
Fisher’s exact test was used to estimate the associ-
ation between CFS and phase angle values: p-values,
odds ratio (OR) and respective 95% confidence inter-
vals were obtained.
The relation among propofol dose at LOC, body size
descriptors and phase angle was determined by linear re-
gression analysis.
Statistical analyses were performed using GraphPad
Prism 8.2.0 software (GraphPad Prism, San Diego, Cali-
fornia). A p-value < 0.05 was considered to be statisti-
cally significant.
Results
Twenty adult patients (Age < 65 group) and twenty older
patients (Age ≥ 65 group) were enrolled for participation in
the study from April 2016 to March 2017. Patient’s demo-
graphics and comorbidity indexes are presented in Table 1.
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The body composition of each patient evaluated by
BIA is demonstrated in Table 2. The mean percentage of
FFM in Age < 65 and Age ≥ 65 groups is 33.5 and 30.2%,
respectively. There is a good agreement between the
LBW values obtained by the Janmahasatian equation
(LBWj) [25] and FFM values measured by the BCM in
both groups (Fig. 1).
With respect to phase angle values, Fig. 2 shows that
lower values were observed in Age ≥ 65 group in com-
parison with those observed in the Age < 65 group. Fig-
ure 2 also shows that in Age ≥ 65 group the median
standardized phase angle value (z-score) was lower than
expected from a reference healthy population with the
same sex, age and BMI.
No relevant changes in heart rate, blood pressure and
BIS values were observed following opioid administration.
Table 3 shows that the median absolute dose of
propofol to LOC was lower in the Age ≥ 65 group
(p = 0.005). Despite the lower propofol induction dose,
the mean variation of MAP (mean arterial pressure)
was higher in the Age ≥ 65 group (p = 0.046). In this
group, 6 patients showed a variation of MAP values
before and after propofol dose higher than 40%.
These patients were treated with ephedrine and fluid
boluses to return MAP to baseline levels. No changes
in heart rate that have required intervention were ob-
served during propofol induction. Table 3 also shows
that mean propofol plasma concentration after induc-
tion of general anesthesia was higher in the Age ≥ 65
group.
Clinical frailty scale scores are presented in Table 4.
These scores are statistically significant different be-
tween groups (p < 0.001). Actually, in the Age ≥ 65
group, 60% of patients were classified as apparently vul-
nerable or frail and in the Age < 65 group all the pa-
tients were classified as very fit, well or managing well.
Figure 3 shows that lower z-scores are associated with
high vulnerability CFS scores. The patients with a CFS
score equal to or higher than 4 have been 23 times more
often classified with a z-score lower than zero than pa-
tients with a CFS score lower than 4 (OR 0.044; 95%
confidence interval 0.0072 to 0.2630; p = 0.0002).
Regarding the regression analysis, Fig. 4 indicates that
propofol dose was similarly related to TBW and FFM in
both groups (r2 = 0.39 vs 0.36 and r2 = 0.48 vs 0.45).
When the TBW is scaled by the corresponding phase
angle values, Age ≥ 65 group shows a stronger relation-
ship than that observed in the Age < 65 group (r2 = 0.63
vs 0.23). Figure 4 also compares the propofol doses at
LOC with those that would be obtained using a standard
bolus approach. Accordingly, the use of a bolus dose
of propofol based on TBW (1 mg•TBW) would result
in inappropriately low doses in some patients of the
Age ≥ 65 group (Fig. 4d). Conversely, the use of the
standard dose (2 mg•TBW) would be adequate for the
Age < 65 group (Fig. 4a).
Discussion
In this study, older patients required a lower propofol
dose than adult patients to clinical LOC when propo-
fol was administered at a fixed infusion rate. In the
Age ≥ 65 group, the relationship between propofol
dose and TBW scaled by the corresponding phase
angle values is stronger than the correlation between
propofol dose and TBW or FFM.
In the present study, LOC was defined clinically by
“loss of eye-lash reflex” and “loss of response to name
calling”. BIS values were not used to guide propofol
dose because of the previously reported delay between
clinical recognition of LOC and the decrease in BIS
values [26], which may lead to propofol overdosing.
The same infusion rate of propofol was adopted in
the Age < 65 and Age ≥ 65 groups because propofol
infusion rate has a critical impact on the dose and
time required to induction of general anesthesia [27–
Table 1 Patient demographic characteristics and comorbidity
indexes
Variables Age < 65 group Age≥ 65 group
Age (years) 42.85 (26)a 77.8 (11)a
Gender
Female 14 (70)b 12 (60)b
Male 6 (30)b 8 (40)b
ASA
I 7 (35)b 1 (5)b
II 12 (60)b 15 (75)b
III 1 (5)b 4 (20)b
Charlson Comorbidity index
0–1 18 (90)b 13 (65)b
2–3 2 (10)b 6 (30)b
4–5 0 1 (5)b
ASA American society of anesthesiology
aData are present as mean (CV %)
bData are presented as frequency (%)
Table 2 Body composition according to bioelectrical
impedance analysis
Variables Age < 65 group Age ≥ 65 group p-value
Body mass index (kg/m2) 25.9 (15) 24.3 (14) 0.09
Total body weight (kg) 70.2 (21) 63.0 (18) 0.18
Fat free mass (kg) 49.0 (23) 41.9 (23) 0.04
Fat free mass (%) 70.0 (10) 66.2 (10) 0.09
Fat mass (kg) 21.1 (33) 21.1 (24) 0.97
Data are present as mean (CV%)
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29]. The use of different infusion rates appear alone
to result in different dosing regimens and correlations
levels. Additionally, a lower infusion rate (2000 mg/h)
than that exposed in the recommendations (7200 mg/
h) have been selected. According to Chan et al. [30]
the use of slower infusion rates allowed more time to
observe the specific clinical endpoint of LOC. It has
also been published in several studies that the mean
MAP variations were lower when slower propofol in-
fusion rates (2000–3000 mg/h) were used [30–32].
For the fixed infusion rate adopted in the present
study, propofol dose to LOC in adult patients was
Fig. 1 Bland–Altman plots - Janmahasatian formula vs. body impedance analysis in Age < 65 group (a) and Age≥ 65 group (b). The 95% limits of
agreement are shown as dashed lines. BMI | Body mass index (kg/m2)
Fig. 2 Phase angle reference values. a, b and c represent the distribution of phase angle values according to age, BMI and sex. Vertical dashed
lines represent lower phase angle reference value in healthy adult population. d shows the distribution of the standardized phase angle, z score,
[z score = (observed phase angle-mean reference phase angle)/SD reference phase angle] for specific age, sex and BMI categories. BMI | Body
mass index (kg/m2). F | Female. M | Male. SD | Standard deviation
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similarly correlated with TBW and FFM, as also no-
ticed by Ingrand et al. [8]. Similar considerations were
herein observed in the results obtained for the Age ≥
65 group (Fig. 4). These results are in accordance to
the results of body composition evaluation by BIA
providing that the expecting differences in FFM and
FM associated with age [5] were not verified in the
present study (Table 2).
By comparing the correlations obtained using TBW as
a size descriptor (Table 3), it can also be seen that a
lower dose per kg is required in older patients. This ob-
servation is in line with previous literature [7], whereby
lower doses of propofol are recommended for older pa-
tients. However, the standard bolus dose (1 mg/kg based
on TBW) may result in inappropriately low doses in
some older patients (Fig. 4d).
The results obtained when TBW is scaled by the cor-
responding phase angle values showed a stronger
correlation level in the Age ≥ 65 group (Fig. 4f). This
correlation level was not verified in the Age < 65 group
(Fig. 4c). Other authors have previously concluded that
BIA derived phase angle can be associated with frailty
and that phase angle values can be interpreted as a glo-
bal marker of health in aging [15]. This fact was noted
in the present study, namely on the association observed
between standardized phase angle values and CFS scor-
ing in the Age ≥ 65 group (Fig. 2). Therefore, the differ-
ences between the correlation levels obtained for the
scalar TBW•θ in both groups appear to be related to the
differences in the registered frail scores.
A small number of studies have previously assessed
the effect of frailty as an independent PK predictor to
determine thiopental [33] and propofol [34] dose. Add-
itionally, it has been recommended that perioperative
analgesia protocols should be individualized in frail pa-
tients [1, 3].
With respect to propofol plasma levels (Table 2), a
higher value was found in older patients, thus corrob-
orating the age-related decrease in volume of distribu-
tion and inter-compartmental clearance expected in
these patients [5, 35]. Higher propofol plasma levels
predispose older patients to cardiovascular side effects
associated to propofol. In this study, the higher mean
MAP variation was observed in the Age ≥ 65 group
(Table 2). A slow induction has already been recom-
mended for older patients in order to minimize post-
induction hypotension [7]. Thus, when infusion rates
higher than those adopted in this study are consid-
ered, increased MAP variations may be expected.
Consequently, since low MAP and deep hypnosis is a
predictor of excessive hospital length of stay and
post-operative mortality [36], slow titration and moni-
toring of propofol action is judicious in this group of
patients during induction of general anesthesia.
There are potential limitations associated to this
study specifically the delay between clinical LOC and
blood sample collection. Nevertheless, the average
time was not significantly different between groups
and the range of plasma concentrations measured
ascertained the differences observed in propofol dose
to LOC and hemodynamic side effects. Additionally,
in this study, each patient received a standardized
dose of fentanyl or remifentanil, according to the
scheduled surgery. Notwithstanding the synergistic
interaction between opioids and propofol for the sup-
pression of purposeful movement to skin incision, the
effect of opioids in the absence of a painful stimulus
is limited [37]. It was shown by Milne et al. [38] that
low target remifentanil concentrations (< 4 ng/mL)
have low hypnotic potency and therefore a limited
impact on propofol dose requirements when a painful
stimuli is not applied. With respect to fentanyl, it has
Table 3 Propofol dose until loss of consciousness
Variables Age < 65 group Age ≥ 65 group p-value
Propofol (mg) 90 (40)a 68.5 (36)a 0.005
Propofol (mg/kg of TBW) 1.24 (30)a 1.09 (25)a 0.05
Time to LOC (min) 2.95 (1.18)b 2.17 (0.78)b 0.02
MAP variationd (mmHg) 19.62 (67)c 29.04 (54)c 0.05
Plasma [Propofol] (μg/mL) 3.96 (39)c 7.68 (34)c < 0.001
Time after LOCe (min) 1.6 (1.3)b 1.5 (1)b 0.84
BISf 49.5 (22)a 46 (27)a 0.88
LOC Loss of consciousness, MAP Mean arterial pressure, TBW Total
body weight
aData are presented as median (CV%)
bData are presented as mean (SD)
cData are presented as mean (CV%)
dVariation = [(MAP before propofol – MAP after propofol)/MAP
before propofol]*100
eTime after LOC is the time when arterial blood sample was obtained
after LOC
fBispectral index value at the time of blood sample collection
Table 4 Clinical frailty scale
Age <
65
group
Clinical frailty scale Age ≥
65
group
Item Description
2 (10)a 1 Very fit 0
11 (55)a 2 Well 2 (10)a
7 (35)a 3 Managing well 6 (30)a
0 4 Apparently vulnerable 7 (35)a
0 5 Mildly frail 4 (20)a
0 6 Moderately frail 1 (5)a
0 7 Severely frail 0
0 8 Very severely frail 0
0 9 Terminally ill 0
aData are presented as frequency (%)
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been concluded that the interaction between fentanyl
and propofol for LOC is minor [39, 40].
Conclusion
For the fixed infusion rate of propofol (2000 mg/h) used
in the present study, a lower dose of propofol based on
TBW is suitable in older patients when compared to that
required for adult patients. Nevertheless, the cumulative
declines of physiologic systems and the baseline vulner-
ability to adverse outcomes specific of frail patients
should also be measured to estimate individualized dos-
age profiles. Determination of phase angle appears to be
Fig. 3 Standardized phase angle (z-score) and clinical frail scale scores for each patient. CFS | Clinical frail scale
Fig. 4 Propofol dose at LOC. a, b and c show, respectively, the correlations of propofol induction dose with TBW, FFM and TBW•phase angle of
Age < 65 group. d, e and f illustrate, respectively, the correlations of propofol induction dose with TBW, FFM and TBW•phase angle of Age≥ 65
group. Grey line in a and d represents the function equivalent to the standard adult and older propofol dose (2 mg•TBW in a and 1mg•TBW in d),
respectively. BMI | Body mass index. FFM | Fat free mass. LOC | Loss of consciousness. TBW | Total body weight
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an easy and reliable tool to assess frailty in older pa-
tients. A multivariate analysis comparing adult and older
healthy patients with adult and older frail patients is ne-
cessary to accurately determine the effect of frailty on
propofol induction dose.
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